REFERENCES
1. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125:3049-58.
2. Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100.
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
4. Mateos MV, González-Calle V. Smoldering multiple myeloma: Who and when to treat. Clin Lymphoma Myeloma Leuk 2017;17:716-22.
5. Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood 2019;133:2484-94.
6. Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48:4-12.
8. Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: Definition, presentation, and treatment. Curr Oncol Rep 2019;21:8.
9. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J 2018;8:7.
10. Silbermann R, Roodman GD. Myeloma bone disease: Pathophysiology and management. J Bone Oncol 2013;2:59-69.
11. Delgado-calle J. Osteocytes and their messengers as targets for the treatment of multiple myeloma. Clinic Rev Bone Miner Metab 2017;15:49-56.
13. Delgado-Calle J, Kurihara N, Atkinson EG, et al. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget 2019;10:2709-21.
14. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19:370-81.
15. Delgado-Calle J, Anderson J, Cregor MD, et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia 2017;31:2686-94.
16. McDonald MM, Reagan MR, Youlten SE, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 2017;129:3452-64.
17. Eda H, Santo L, Wein MN, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: A potential therapeutic strategy for myeloma bone disease. J Bone Miner Res 2016;31:1225-34.
18. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 2016;16:373-86.
19. Hideshima T, Anderson KC. Signaling pathway mediating myeloma cell growth and survival. Cancers (Basel) 2021;13:216.
21. Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 2015;263:160-72.
22. Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and Disease. Physiol Rev 2017;97:1235-94.
24. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
25. Colombo M, Galletti S, Garavelli S, et al. Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget 2015;6:26826-40.
26. Komatsu H, Chao MY, Larkins-Ford J, et al. OSM-11 facilitates LIN-12 Notch signaling during Caenorhabditis elegans vulval development. PLoS Biol 2008;6:e196.
27. Cordle J, Johnson S, Tay JZ, et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct Mol Biol 2008;15:849-57.
28. Cordle J, Redfieldz C, Stacey M, et al. Localization of the delta-like-1-binding site in human Notch-1 and its modulation by calcium affinity. J Biol Chem 2008;283:11785-93.
29. Raya A, Kawakami Y, Rodríguez-Esteban C, et al. Notch activity acts as a sensor for extracellular calcium during vertebrate left-right determination. Nature 2004;427:121-8.
30. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678-89.
31. D'Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene 2008;27:5148-67.
32. Tetering G, Vooijs M. Proteolytic cleavage of Notch: "HIT and RUN". Curr Mol Med 2011;11:255-69.
33. Kitagawa M. Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators. J Biochem 2016;159:287-94.
34. Kovall RA. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene 2008;27:5099-109.
35. Borggrefe T, Oswald F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009;66:1631-46.
36. Aster JC, Pear WS, Blacklow SC. The varied roles of Notch in cancer. Annu Rev Pathol 2017;12:245-75.
38. Colombo M, Mirandola L, Platonova N, et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia 2013;27:1009-18.
39. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-80.
40. Jundt F, Pröbsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
41. Skrtić A, Korać P, Krišto DR, Ajduković Stojisavljević R, Ivanković D, Dominis M. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. Hum Pathol 2010;41:1702-10.
42. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004;104:3697-704.
43. Delgado-Calle J, Anderson J, Cregor MD, et al. Bidirectional Notch signaling and Osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res 2016;76:1089-100.
44. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
45. Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ. Identification of primary MAFB target genes in multiple myeloma. Exp Hematol 2009;37:78-86.
46. Ordoñez R, Kulis M, Russiñol N, et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res 2020;30:1217-27.
47. Jundt F, Pröbsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
48. Pisklakova A, Grigson E, Ozerova M, Chen F, Sullivan DM, Nefedova Y. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment. Cancer Biol Ther 2016;17:477-85.
49. Schwarzer R, Nickel N, Godau J, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J 2014;4:e217.
50. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9.
51. Ramakrishnan V, Ansell S, Haug J, et al. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 2012;26:340-8.
52. Zweidler-McKay PA, He Y, Xu L, et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005;106:3898-906.
53. Colombo M, Galletti S, Bulfamante G, et al. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget 2016;7:56013-29.
54. Li M, Chen F, Clifton N, et al. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther 2010;9:3200-9.
55. Colombo M, Platonova N, Giannandrea D, Palano MT, Basile A, Chiaramonte R. Re-establishing apoptosis competence in bone associated cancers via communicative reprogramming induced through Notch signaling inhibition. Front Pharmacol 2019;10:145.
56. Mirandola L, Apicella L, Colombo M, et al. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 2013;27:1558-66.
57. Guo D, Li C, Teng Q, Sun Z, Li Y, Zhang C. Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma. Neoplasma 2013;60:33-40.
58. Sabol HM, Amorim T, Kurihara N, et al. Autocrine and paracrine Notch receptor 3 signaling in the myeloma niche stimulates tumor growth and bone destruction. J Bone Miner Res 2020;35:98.
59. Chiron D, Maïga S, Descamps G, et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis 2012;48:247-53.
60. Berenstein R, Nogai A, Waechter M, et al. Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223. Mol Carcinog 2016;55:1927-39.
61. Xu D, Hu J, Xu S, et al. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia 2012;26:1402-5.
62. Xu D, Hu J, De Bruyne E, et al. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun 2012;428:518-24.
63. Yin L. Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions. J Biol Chem 2005;280:15666-72.
64. Hu J, Zhu X, Lu Q. Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action. J Int Med Res 2013;41:1017-26.
65. Das DS, Das A, Ray A, et al. Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells. Clin Cancer Res 2017;23:4280-9.
66. Wang Y, Li W, Huang F, et al. Synthesis of sophocarpine triflorohydrazone and its proliferation inhibition and apoptosis induction activity in myeloma cells through Notch3-p53 signaling activation. Environ Toxicol 2021;36:484-90.
67. Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol 2021;17:29-35.
68. Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 2013;4:2186-207.
69. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
70. Colombo M, Garavelli S, Mazzola M, et al. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica 2020;105:1925-36.
71. Muguruma Y, Yahata T, Warita T, et al. Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J 2017;7:650.
72. Ding Y, Shen Y. Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis. Biochem Biophys Res Commun 2015;467:717-22.
73. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
74. Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008;27:663-74.
75. Ria R, Melaccio A, Racanelli V, Vacca A. Anti-VEGF drugs in the treatment of multiple myeloma patients. J Clin Med 2020;9:1765.
77. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003;17:1961-6.
78. Palano MT, Giannandrea D, Platonova N, et al. Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells. Cancers (Basel) 2020;12:2600.
79. Saltarella I, Frassanito MA, Lamanuzzi A, et al. Homotypic and heterotypic activation of the Notch pathway in multiple myeloma-enhanced angiogenesis: A novel therapeutic target? Neoplasia 2019;21:93-105.
80. Mulcrone PL, Edwards SKE, Petrusca DN, Haneline LS, Delgado-Calle J, Roodman GD. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci Rep 2020;10:17319.
81. Allen MR, Burr DB. . Bone modeling and remodeling. In: Burr DB, Allen MR, editors. Basic and Applied Bone Biology. Netherlands: Elsevier; 2014. p. 75-90.
82. Delgado-Calle J, Bellido T. Osteocytes and skeletal pathophysiology. Curr Mol Biol Rep 2015;1:157-67.
84. Bai S, Kopan R, Zou W, et al. NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. J Biol Chem 2008;283:6509-18.
85. Fukushima H, Nakao A, Okamoto F, et al. The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis. Mol Cell Biol 2008;28:6402-12.
86. Yamada T, Yamazaki H, Yamane T, et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. Blood 2003;101:2227-34.
87. Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008;149:3890-9.
88. Hilton MJ, Tu X, Wu X, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008;14:306-14.
89. Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006;281:6203-10.
90. Sciaudone M, Gazzerro E, Priest L, Delany AM, Canalis E. Notch 1 impairs osteoblastic cell differentiation. Endocrinology 2003;144:5631-9.
91. Tezuka K, Yasuda M, Watanabe N, et al. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 2002;17:231-9.
92. Canalis E, Adams DJ, Boskey A, Parker K, Kranz L, Zanotti S. Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling. J Biol Chem 2013;288:25614-25.
93. Liu P, Ping Y, Ma M, et al. Anabolic actions of Notch on mature bone. Proc Natl Acad Sci U S A 2016;113:E2152-61.
94. Marino S, Petrusca DN, Roodman GD. Therapeutic targets in myeloma bone disease. Br J Pharmacol 2019; doi: 10.1111/bph.14889.
95. Silbermann R, Roodman GD. Current controversies in the management of myeloma bone disease. J Cell Physiol 2016;231:2374-9.
96. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011;17:1278-86.
98. Colombo M, Thümmler K, Mirandola L, et al. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget 2014;5:10393-406.
99. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med 2011;17:1235-41.
100. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011;17:1231-4.
101. Xu S, Evans H, Buckle C, et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 2012;26:2546-9.
102. Guo J, Fei C, Zhao Y, et al. Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget 2017;8:55405-21.
103. Canalis E, Bridgewater D, Schilling L, Zanotti S. Canonical Notch activation in osteocytes causes osteopetrosis. Am J Physiol Endocrinol Metab 2016;310:E171-82.
104. Schwarzer R, Kaiser M, Acikgoez O, et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008;22:2273-7.
105. Ferrari A, McAndrews K, Nelson JH, et al. Bone-targeted inhibition of Notch signaling blocks tumor growth and prevents bone loss without inducing gut toxicity in immunodeficient and immunocompetent murine models of established multiple myeloma. J Bone Miner Res 2019;34:32.
106. Moore G, Annett S, McClements L, Robson T. Top Notch targeting strategies in cancer: A detailed overview of recent insights and current perspectives. Cells 2020;9:1503.
107. Fabbro D, Bauer M, Murone M, Lehal R. Notch inhibition in cancer: Challenges and opportunities. Chimia (Aarau) 2020;74:779-83.
108. Nefedova Y, Gabrilovich D. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat 2008;11:210-8.
109. Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88.
110. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61.
111. Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003;278:46107-16.
112. Lehal R, Zaric J, Vigolo M, et al. Pharmacological disruption of the Notch transcription factor complex. Proc Natl Acad Sci U S A 2020;117:16292-301.
